Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Brockstein

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Cancer Survivorship : Research and Practice|July 17, 2015
Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visitCarol A Rosenberg, Carol Flanagan, Bruce Brockstein, et al.
Head & Neck|November 23, 2005
Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiationJeri A Logemann, Alfred W Rademaker, Barbara Roa Pauloski, et al.
Journal of Palliative Medicine|October 25, 2014
Outpatient advance care planning for patients with metastatic cancer: a pilot quality improvement initiativeJennifer Obel, Bruce Brockstein, Michael Marschke, et al.
Cancer|October 8, 2016
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)Jonas A de Souza, Bonnie J Yap, Kristen Wroblewski, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 9, 2007
A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scoresSusan Yount, Marcy List, Hongyan Du, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trialEzra E W Cohen, Daniel J Haraf, Marcy A List, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2012
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancerMatthew G Fury, Eric Sherman, Donna Lisa, et al.
Cancers|February 13, 2026
Operationalizing Next-Generation Sequencing in a Community-Based Academic Cancer Center: Workflow, Integration, and ImpactGayathri Moorthy, Annette Sereika, Bruce Brockstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancerEzra E W Cohen, Daniel J Haraf, Rangesh Kunnavakkam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in MelanomaDaniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Cancer Survivorship : Research and Practice|July 17, 2015
Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visitCarol A Rosenberg, Carol Flanagan, Bruce Brockstein, et al.
Head & Neck|November 23, 2005
Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiationJeri A Logemann, Alfred W Rademaker, Barbara Roa Pauloski, et al.
Journal of Palliative Medicine|October 25, 2014
Outpatient advance care planning for patients with metastatic cancer: a pilot quality improvement initiativeJennifer Obel, Bruce Brockstein, Michael Marschke, et al.
Cancer|October 8, 2016
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)Jonas A de Souza, Bonnie J Yap, Kristen Wroblewski, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 9, 2007
A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scoresSusan Yount, Marcy List, Hongyan Du, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trialEzra E W Cohen, Daniel J Haraf, Marcy A List, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2012
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancerMatthew G Fury, Eric Sherman, Donna Lisa, et al.
Cancers|February 13, 2026
Operationalizing Next-Generation Sequencing in a Community-Based Academic Cancer Center: Workflow, Integration, and ImpactGayathri Moorthy, Annette Sereika, Bruce Brockstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancerEzra E W Cohen, Daniel J Haraf, Rangesh Kunnavakkam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in MelanomaDaniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Pageof 4